Alzheimer’s Society responds to Cochrane review of ‘Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease’ - April 2026.
Alzheimer’s Society responds to Cochrane review of ‘Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease’ - April 2026.
The number of people whose deaths were due to dementia has been steadily increasing year on year. The latest data shows that dementia was recorded as the leading cause of death in the UK.
The number of people whose deaths were due to dementia has been steadily increasing year on year. The latest data shows that dementia was recorded as the leading cause of death in the UK.
...
Trontinemab is one of the latest disease-modifying drugs currently being tested in late-stage clinical trials. Here’s what we know about this potential new treatment for Alzheimer's disease.
Trontinemab is one of the latest disease-modifying drugs currently being tested in late-stage clinical trials. Here’s what we know about this potential new treatment for Alzheimer's disease.
Semaglutide (the essential ingredient in Rybelsus, Ozempic and Wegovy) is currently in the headlines after the disappointing news that clinical trials showed it does not help slow Alzheimer’s disease. Here’s what we know about this drug.
Semaglutide (the essential ingredient in Rybelsus, Ozempic and Wegovy) is currently in the headlines after the disappointing news that clinical trials showed it does not help slow Alzheimer’s disease. Here’s what we know about this drug.
Dementia Support Line